A Phase II Study of XL184 (Cabozantinib) for Metastatic Triple-Negative Breast Cancer

Trial Profile

A Phase II Study of XL184 (Cabozantinib) for Metastatic Triple-Negative Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2016

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Advanced breast cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Status changed from recruiting to completed as reported at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top